Efficacy and safety of interferon beta-1b sc in older RRMS patients - A posthoc analysis of the beyond study

Christian Lampl, Stefan Nagl, Barry Arnason, Giancarlo Comi, Paul Oconnor, Stuart Cook, Douglas Jeffery, Ludwig Kappos, Massimo Filippi, Karola Beckmann, Timon Bogumil, Christoph Pohl, Rupert Sandbrink, Hans Peter Hartung

Research output: Contribution to journalArticlepeer-review

Abstract

Evidence of a significant improvement of IFNB-1b in clinical severity in the older population with RRMS has not been established so far. The aim of this exploratory post hoc analysis of the 250 mcg IFNB-1b group of the BEYOND study is to compare the efficacy and safety of older versus younger patients using a cut-off at the age of 50 and at the age of 40, respectively. There was no difference between age groups in adjusted relapse risk (age 50 cut-off: P = 0.482, age 40 cut-off: P = 0.073) nor in adjusted time to confirmed EDSS progression (age 50 cut-off: P = 0.096, age 40 cut-off: P = 0.189). There were no significant differences between patients

Original languageEnglish
Pages (from-to)1838-1845
Number of pages8
JournalJournal of Neurology
Volume260
Issue number7
DOIs
Publication statusPublished - Jul 2013

Keywords

  • Disease modifying therapy
  • Interferon beta-1b
  • Older population
  • RRMS

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Fingerprint Dive into the research topics of 'Efficacy and safety of interferon beta-1b sc in older RRMS patients - A posthoc analysis of the beyond study'. Together they form a unique fingerprint.

Cite this